...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases

| Print |
Tuesday, 03 December 2013 10:00 (UTC + 1)

Protagen logo neu

Dortmund, Germany, December 3, 2013 / B3C newswire / -Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”


About Protagen
PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.


Contact

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T: +49 (0) 231 9742 6300
F: +49 (0) 231 9742 6301
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Press Inquiries
Dr. Georg Lautscham
CBO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T:+49 (0) 231 9742 6300
F:+49 (0) 231 9742 6301
This e-mail address is being protected from spambots. You need JavaScript enabled to view it